|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||6.43 - 6.69|
|52 Week Range||3.28 - 8.87|
|Beta (5Y Monthly)||0.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2023 - Feb 24, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.36|
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid). NEXLIZET will be featured on Keselowski’s N
PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.